Pure Global

Acquired genetic alteration IVDs

Access comprehensive regulatory information for Acquired genetic alteration IVDs in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIb is sponsored by Qiagen Pty Ltd, manufactured by Qiagen GmbH in Germany. The device registration started on March 05, 2020.

This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.

Free Database
Powered by Pure Global AI
TGA ARTG Official Data
Class IIb
Class IIb
Acquired genetic alteration IVDs
Australia TGA ARTG Registered Device
Good Name: Qiagen Pty Ltd - Acquired genetic alteration IVDs
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Intended Purpose

The therascreen PIK3CA RGQ PCR kit is intended for use as a companion diagnostic test, to aid clinicians in identification of breast cancer patients who may be eligible for treatment with PIQRAY (alpelisib) based on a PIK3CA mutation detected result.

Device Classification
Risk Class
Class IIb
Product Type
IVD
ARTG Category
IVD
Registration Information
Start Date
March 05, 2020
Effective Date
March 05, 2020
Sponsor
Manufacturer
Country
Germany
Address
Qiagen Str 1, Hilden, 40724